Apr 15 2021 - Apr 18 2021
WCN’21 – World Congress of Nephrology
Montreal, Canada
Press releases
Eleva secures up to EUR 60 million to advance a drug candidate, appoints new board member
Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through pre-clinical stages.
Navigo Proteins and Eleva Announce Successful Development of an Affinity Chromatography Resin Customized for the Efficient Purification of Human Complement-Factor H
Custom Affinity Chromatography Resin Promises High Yield Purification in Clinical and Commercial GMP Downstream Processing.
Eleva’s drug candidate to be examined for use in Covid-19 treatment
Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through pre-clinical stages.
